Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variant
In the context of Omicron SARS-CoV-2 infection, administering nirmatrelvir-ritonavir to patients at high risk of severe disease improves health outcomes and reduces costs. Nirmatrelvir-ritonavir is 100% likely to be cost-effective at a willingness to pay of €2,000 per QALY.
Authors
- Sophie Marbaix
- Keliane Liberman (ORCID: https://orcid.org/0000-0003-3224-7908)
- Steven Simoens (ORCID: https://orcid.org/0000-0002-9512-2005)
- Pascal Van Bleyenbergh
- Philippe Clevenbergh
- Dimitri Dehenau
Institutions
- University of Mons (BE)
- Centre Hospitalier Universitaire Brugmann (BE)
- Pfizer (Belgium) (BE)
- KU Leuven (BE)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-02-03
- DOI
- https://doi.org/10.3389/fpubh.2024.1432821
- Citations
- 2
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Pfizer